Labeltemplate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
'''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | '''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | ||
==[[Drug project disclaimer | ==[[Drug project disclaimer|Disclaimer]]== | ||
==[[{{BASEPAGENAME}}/black box warning|{{fontcolor|#FF0000|Black Box Warning}}]]== | ==[[{{BASEPAGENAME}}/black box warning|{{fontcolor|#FF0000|Black Box Warning}}]]== | ||
| Line 11: | Line 11: | ||
==Overview== | ==Overview== | ||
{{BASEPAGENAME}} is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown <span style="background:#000000;">'''[[{{BASEPAGENAME}}/black box warning|{{fontcolor|#FF0000|here}}]]'''</span>. | {{BASEPAGENAME}} is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown <span style="background:#000000;">'''[[{{BASEPAGENAME}}/black box warning|{{fontcolor|#FF0000|here}}]]'''</span>. Common adverse reactions include _______. | ||
==Adult Indications and Dosage== | ==[[{{BASEPAGENAME}}/adult indications and dosage|Adult Indications and Dosage]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/adult indications and dosage#FDA-Labeled Indications and Dosage (Adult)|FDA-Labeled Indications and Dosage (Adult)]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/adult indications and dosage#FDA-Labeled Indications and Dosage (Adult)|FDA-Labeled Indications and Dosage (Adult)]]'''</BIG></BIG> | ||
| Line 19: | Line 19: | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/adult indications and dosage#Off-Label Use and Dosage (Adult)|Off-Label Use and Dosage (Adult)]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/adult indications and dosage#Off-Label Use and Dosage (Adult)|Off-Label Use and Dosage (Adult)]]'''</BIG></BIG> | ||
==Pediatric Indications and | ==[[{{BASEPAGENAME}}/pediatric indications and dosage|Pediatric Indications and Dosag]]e== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/pediatric indications and dosage#FDA-Labeled Indications and Dosage (Pediatric)|FDA-Labeled Indications and Dosage (Pediatric)]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/pediatric indications and dosage#FDA-Labeled Indications and Dosage (Pediatric)|FDA-Labeled Indications and Dosage (Pediatric)]]'''</BIG></BIG> | ||
| Line 25: | Line 25: | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/pediatric indications and dosage#Off-Label Use and Dosage (Pediatric)|Off-Label Use and Dosage (Pediatric)]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/pediatric indications and dosage#Off-Label Use and Dosage (Pediatric)|Off-Label Use and Dosage (Pediatric)]]'''</BIG></BIG> | ||
== | ==[[{{BASEPAGENAME}}/contraindications|Contraindications]]== | ||
==[[{{BASEPAGENAME}}/warnings|Warnings]]== | ==[[{{BASEPAGENAME}}/warnings|Warnings]]== | ||
==Adverse Reactions== | ==[[{{BASEPAGENAME}}/adverse reactions|Adverse Reactions]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/adverse reactions#Clinical Trials Experience|Clinical Trials Experience]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/adverse reactions#Clinical Trials Experience|Clinical Trials Experience]]'''</BIG></BIG> | ||
| Line 37: | Line 37: | ||
==[[{{BASEPAGENAME}}/drug interactions|Drug Interactions]]== | ==[[{{BASEPAGENAME}}/drug interactions|Drug Interactions]]== | ||
==Use in Specific Populations== | ==[[{{BASEPAGENAME}}/use in specific populations|Use in Specific Populations]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/use in specific populations#Pregnancy|Pregnancy]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/use in specific populations#Pregnancy|Pregnancy]]'''</BIG></BIG> | ||
| Line 61: | Line 61: | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/use in specific populations#Immunocompromised Patients|Immunocompromised Patients]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/use in specific populations#Immunocompromised Patients|Immunocompromised Patients]]'''</BIG></BIG> | ||
== | ==[[{{BASEPAGENAME}}/routes and preparations|Routes and Preparations]]== | ||
==[[{{BASEPAGENAME}}/IV compatibility|IV Compatibility]]== | ==[[{{BASEPAGENAME}}/IV compatibility|IV Compatibility]]== | ||
| Line 71: | Line 67: | ||
==[[{{BASEPAGENAME}}/overdosage|Overdosage]]== | ==[[{{BASEPAGENAME}}/overdosage|Overdosage]]== | ||
==Pharmacology== | ==[[{{BASEPAGENAME}}/pharmacology|Pharmacology]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/pharmacology#Mechanism of Action|Mechanism of Action]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/pharmacology#Mechanism of Action|Mechanism of Action]]'''</BIG></BIG> | ||
| Line 87: | Line 83: | ||
==[[{{BASEPAGENAME}}/how supplied|How Supplied]]== | ==[[{{BASEPAGENAME}}/how supplied|How Supplied]]== | ||
==Images== | ==[[{{BASEPAGENAME}}/images|Images]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/images#Drug Images|Drug Images]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/images#Drug Images|Drug Images]]'''</BIG></BIG> | ||
| Line 93: | Line 89: | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/images#Package and Label Display Panel|Package and Label Display Panel]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/images#Package and Label Display Panel|Package and Label Display Panel]]'''</BIG></BIG> | ||
==Patient Information== | ==[[{{BASEPAGENAME}}/patient information|Patient Information]]== | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/patient information#Patient Information from FDA|Patient Information from FDA]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/patient information#Patient Information from FDA|Patient Information from FDA]]'''</BIG></BIG> | ||
| Line 99: | Line 95: | ||
: <BIG><BIG>'''[[{{BASEPAGENAME}}/patient information#Patient Information from NLM|Patient Information from NLM]]'''</BIG></BIG> | : <BIG><BIG>'''[[{{BASEPAGENAME}}/patient information#Patient Information from NLM|Patient Information from NLM]]'''</BIG></BIG> | ||
== | ==Precautions with Alcohol== | ||
Alcohol-{{BASEPAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | Alcohol-{{BASEPAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
| Line 106: | Line 102: | ||
==[ | ==[http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm Drug Shortage Status]== | ||
==[ | ==[http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{BASEPAGENAME}}}}}}/price Price]== | ||
Latest revision as of 15:48, 21 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For information about (Generic Name), click here.
Disclaimer
Black Box Warning
Overview
Labeltemplate is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown here. Common adverse reactions include _______.
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Routes and Preparations
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Information
Precautions with Alcohol
Alcohol-Labeltemplate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.